Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 4 of 4
Full-Text Articles in Psychology
Asenapine Sensitization From Adolescence To Adulthood And Its Potential Molecular Basis, Qing Shu, Rongyin Qin, Yingzhu Chen, Gang Hu, Ming Li
Asenapine Sensitization From Adolescence To Adulthood And Its Potential Molecular Basis, Qing Shu, Rongyin Qin, Yingzhu Chen, Gang Hu, Ming Li
Department of Psychology: Faculty Publications
Asenapine is a new antipsychotic drug that induces a long-lasting behavioral sensitization in adult rats. The present study investigated the developmental impacts of adolescent asenapine treatment on drug sensitivity and on 3 proteins implicated in the action of antipsychotic drugs (i.e. Brainderived neurotrophic factor (BDNF), dopamine D2 receptor, and ΔFosB) in adulthood. Male adolescent Sprague-Dawley rats (postnatal days, P 43-48) were first treated with asenapine (0.05, 0.10 or 0.20 mg/kg, sc) and tested in the conditioned avoidance or PCP (2.0 mg/kg, sc)-induced hyperlocomotion tasks for 5 days. After they became adults (∼P 76), asenapine sensitization was assessed in a …
Effect Of Environmental Cues On Behavioral Efficacy Of Haloperidol, Olanzapine And Clozapine In Rats, Tao Sun, Xinfeng Liu, Ming Li
Effect Of Environmental Cues On Behavioral Efficacy Of Haloperidol, Olanzapine And Clozapine In Rats, Tao Sun, Xinfeng Liu, Ming Li
Department of Psychology: Faculty Publications
Previous studies have reported that context can powerfully modulate the inhibitory effect of an antipsychotic drug on phencyclidine (PCP)-induced hyperlocomotion (a behavioral test used to evaluate putative antipsychotic drugs). The present study investigated the experimental conditions under which environmental stimuli exert their influence through associative conditioning processes. Experiment 1 examined the extent to which prior antipsychotic treatment in the home cages affected a drug’s ability to inhibit PCP-induced hyperlocomotion in a novel motor activity test apparatus. Five days of repeated haloperidol (0.05 mg/kg, sc) and olanzapine (2.0 mg/kg, sc) treatment in the home cages still potentiated their inhibition of PCP-induced …
Long-Lasting Sensitization Induced By Repeated Risperidone Treatment In Adolescent Sprague-Dawley Rats: A Possible D2 Receptor Mediated Phenomenon?, Jing Qiao, Jun Gao, Qing Shu, Qinglin Zhang, Gang Hu, Ming Li
Long-Lasting Sensitization Induced By Repeated Risperidone Treatment In Adolescent Sprague-Dawley Rats: A Possible D2 Receptor Mediated Phenomenon?, Jing Qiao, Jun Gao, Qing Shu, Qinglin Zhang, Gang Hu, Ming Li
Department of Psychology: Faculty Publications
Rationale Risperidone use in children and adolescents for the treatment of various neuropsychiatric disorders (e.g., schizophrenia, autism, disruptive behavior, etc.) has increased substantially in recent decades. However, its long-term effect on the brain and behavioral functions is not well understood. Objective The present study investigated how a short-term risperidone treatment in adolescence impacts antipsychotic response in adulthood in the conditioned avoidance response and phencyclidine (PCP)-induced hyperlocomotion tests. Methods Male adolescent Sprague-Dawley rats (postnatal days [P] 40–44 or 43–48) were first treated with risperidone (0.3, 0.5, or 1.0 mg/kg, subcutaneously (sc)) and tested in the conditioned avoidance or PCP (3.2 mg/kg, …
Adult Response To Olanzapine Or Clozapine Treatment Is Altered By Adolescent Antipsychotic Exposure: A Preclinical Test In The Phencyclidine Hyperlocomotion Model, Qing Shu, Gang Hu, Ming Li
Adult Response To Olanzapine Or Clozapine Treatment Is Altered By Adolescent Antipsychotic Exposure: A Preclinical Test In The Phencyclidine Hyperlocomotion Model, Qing Shu, Gang Hu, Ming Li
Department of Psychology: Faculty Publications
This study examined how repeated olanzapine (OLZ) or clozapine (CLZ) treatment in adolescence alters sensitivity to the same drug in adulthood in the phencyclidine (PCP) hyperlocomotion model. Male adolescent Sprague-Dawley rats (postnatal day (P) 44–48) were first treated with OLZ (1.0 or 2.0 mg/kg, subcutaneously (sc)) or CLZ (10.0 or 20.0 mg/kg, sc) and tested in the PCP (3.2 mg/kg, sc)-induced hyperlocomotion model for five consecutive days. Then a challenge test with OLZ (0.5 mg/kg) or CLZ (5.0 mg/kg) was administered either during adolescence (~P 51) or after the rats matured into adults (~P 76 and 91). During adolescence, repeated …